Kawaguchi H, Ina Y, Ito S, Sato S, Sugiura Y, Tomita H, Ogisu N, Takada K, Yamamoto M, Morishita M, Yoshikawa K
Second Department of Internal Medicine, Nagoya City University, Japan.
Kekkaku. 1996 Mar;71(3):259-65.
Tumor necrosis factor alpha (TNF-alpha) is released from cells of monocyte/macrophage lincage and mediates the development of a variety of clinical and pathomorphological features in various infectious diseases, autoimmune diseases and cancer. In the case of tuberculosis, it is suggested that the release of TNF-alpha in the affected regions and into the circulation could account for the pathological and clinical features such as the development of necrotic lesions and fever and weight loss in TB patients. In the present study, the levels of soluble TNF receptor type I (sTNFR type I) and type II (sTNFR type II) and TNF-alpha in the sera of patients with pulmonary TB were assayed, and we tried to know whether these levels have clinical significance in determining the disease activity in TB patients. The serum levels of both sTNFR types I and II were significantly higher in TB patients (n = 22) who were previously untreated than in the healthy control (n = 14): for sTNFR type I, 2.82 +/- 1.37 ng/ml vs. 1.40 +/- 0.33 ng/ml (p < 0.0001), and for sTNFR type II, 3.83 +/- 1.76 ng/ml vs. 1.62 +/- ng/ml (p < 0.0001). The serum levels of sTNFR types I and II in TB patients showed significant correlations with their serum levels of CRP. The serum levels of TNF-alpha in these TB patients was 2.21 +/- 1.72 pg/ml, whereas TNF-alpha was not detectable in the sera of 9 healthy control. The serum levels of sTNFR type I and II were significantly higher in cavitary TB (n = 17) than in non-cavitary TB (n = 5). When TB patients were treated with antituberculosis drugs and clinical improvements were achieved, the elevated levels of sTNFR type I and TNF-alpha in the sera of same 5 patients measured before starting treatment showed significant decline and the serum levels of sTNFR type II showed also declined, however, the decline was statistically not significant. From all the results obtained in this study, we conclude that the assay of the serum levels of sTNFR in TB patients is useful in the evaluation of the disease activity of TB.
肿瘤坏死因子α(TNF-α)由单核细胞/巨噬细胞系的细胞释放,并介导各种传染病、自身免疫性疾病和癌症中多种临床和病理形态学特征的发展。在结核病中,有人认为TNF-α在受影响区域释放并进入循环可能是导致坏死病变、发热和结核病患者体重减轻等病理和临床特征的原因。在本研究中,检测了肺结核患者血清中可溶性I型TNF受体(sTNFR I型)、II型TNF受体(sTNFR II型)和TNF-α的水平,我们试图了解这些水平在确定结核病患者疾病活动度方面是否具有临床意义。未经治疗的肺结核患者(n=22)血清中sTNFR I型和II型水平显著高于健康对照(n=14):sTNFR I型,2.82±1.37 ng/ml对1.40±0.33 ng/ml(p<0.0001),sTNFR II型,3.83±1.76 ng/ml对1.62±ng/ml(p<0.0001)。肺结核患者血清中sTNFR I型和II型水平与其血清CRP水平显著相关。这些肺结核患者的血清TNF-α水平为2.21±1.72 pg/ml,而9名健康对照者的血清中未检测到TNF-α。空洞型肺结核患者(n=17)血清中sTNFR I型和II型水平显著高于非空洞型肺结核患者(n=5)。当肺结核患者接受抗结核药物治疗并取得临床改善时,开始治疗前检测的同5名患者血清中升高的sTNFR I型和TNF-α水平显著下降,sTNFR II型血清水平也下降,但下降无统计学意义。从本研究获得的所有结果来看,我们得出结论,检测肺结核患者血清中sTNFR水平有助于评估结核病的疾病活动度。